# Patient Acceptable Symptomatic State and Minimal Clinically Important Difference of the Fatigue in Multiple Sclerosis (SeDiF_SEP)

> **NCT03662347** · — · UNKNOWN · sponsor: **Central Hospital, Nancy, France** · enrollment: 2100 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03662347
- **Lead sponsor:** Central Hospital, Nancy, France
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-19
- **Primary completion:** 2022-03
- **Final completion:** 2022-03
- **Target enrollment:** 2100 (ESTIMATED)
- **Last updated:** 2020-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03662347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03662347, "Patient Acceptable Symptomatic State and Minimal Clinically Important Difference of the Fatigue in Multiple Sclerosis (SeDiF_SEP)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03662347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*